**Alkem Laboratories Expands Portfolio with Dual Acquisitions**
Alkem Laboratories Ltd has announced the acquisition of two companies: Adroit Biomed, which specializes in dermatology and cosmetology, and Bombay Ortho Industries, a medical technology firm. These acquisitions are aimed at bolstering Alkem’s presence in high-growth therapeutic areas and enhancing its manufacturing capabilities in the orthopedic implant sector.
The company will acquire Adroit Biomed for ₹140 crore, to be paid in two installments, with the deal expected to finalize by April 1. Adroit Biomed, which reported a turnover of ₹53.55 crore in FY24, will enable Alkem to broaden its dermatology and cosmetology offerings, expand its market reach, and strengthen its omni-channel presence. The payment structure includes adjustments for debt and working capital changes as of the closing date.
Additionally, Alkem will acquire Bombay Ortho Industries for ₹147 crore, payable in four installments, with the transaction anticipated to be completed by June 30. Founded in 2021, Bombay Ortho focuses on hip and knee implants, a crucial segment in India’s expanding medical device market. This acquisition is seen as a strategic move to enhance Alkem’s manufacturing capabilities and leverage Bombay Ortho’s expertise in the orthopedic space.
In its Q3FY25 earnings report, Alkem reported a 6% year-on-year increase in net profit to ₹641 crore, although there was a 9% decline sequentially. Revenue reached ₹3,467 crore, reflecting a 1.4% year-on-year increase but a 2.3% decrease quarter-on-quarter.
B.N. Singh, chairman of Alkem, stated, “The acquisition of Adroit will allow us to diversify our portfolio, improve market penetration, and strengthen our presence in the expanding dermatology and cosmetology segments. Our investment in Bombay Ortho aligns with our strategy for Medtech in India.” Sandeep Singh, managing director of Alkem, added, “Medtech is a rapidly growing sector in India, and there is a significant demand for quality products. Through our acquisitions in the medical devices segment, we aim to address the increasing need for implants in the country.”
Alkem has a diverse portfolio that includes anti-infectives, gastrointestinal, pain management drugs, and supplements, as well as chronic therapy medications for diabetes, neurology, cardiology, dermatology, and urology.
